NIKKEI 225
38,189.54 -216.12 (-0.56%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
81.14 -0.79 (-0.96%) GOLD FUTURES
2,298.30 -4.60 (-0.20%) DOW
37,815.92 -570.17 (-1.49%) Bitcoin GBP
47,956.23 -3,132.37 (-6.13%)
OBI Pharma, Inc. (4174.TWO)
- GlobeNewswire
OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform
Poster Presentations to highlight the latest research on OBI-992 (anti-TROP2 ADC) and OBI’s novel GlycOBI ADC platformTAIPEI, Taiwan, March 18, 2024 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (TPEx: 4174) today announced preclinical data for OBI-992, a potential best-in-class anti-TROP2 Antibody-Drug Conjugate (ADC). When evaluated against comparative TROP2 ADCs, OBI-992 demonstrated greater antitumor efficacy, superior PK/PD properties, and a favorable safety profile across various preclinical animal
- GlobeNewswire
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992
First clinical trial to evaluate the safety and efficacy of OBI-992, a novel antibody - drug conjugate (ADC) targeting TROP2. Dosing of first patient in the Phase 1/2 clinical trial expected in early 2024.TAIPEI, Taiwan, Jan. 03, 2024 (GLOBE NEWSWIRE) -- OBI Pharma, a clinical stage oncology company (4174.TWO), today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for OBI-992, to conduct a Phase 1/2 study of its novel antibody
